Key result
Cardiac CTA-guided preprocedural planning for left atrial appendage occlusion resulted in accurate device sizing in 97.2% of patients and a 100% procedural success rate.
Why the study?
Percutaneous LAAO is approved for stroke prevention in non-valvular AF, but outcomes using cardiac CTA preprocedural planning paired with ICE-guided deployment warranted review.
Does cardiac CTA-guided preprocedural planning combined with ICE-guided deployment result in accurate device sizing and procedural success in patients undergoing LAAO?
Observational (n=71)
No
Does cardiac CTA-guided preprocedural planning combined with ICE-guided deployment result in accurate device sizing and procedural success in patients undergoing LAAO?
Cardiac CTA-guided preprocedural planning combined with ICE-guided deployment for LAAO is associated with high device sizing accuracy (97.2%) and procedural success (100%).
Supports CTA/ICE-guided LAAO feasibility in this series; hypothesis-generating and requires prospective validation before practice change.
We reviewed the periprocedural events, accuracy of device selection, and outcomes of a series of patients receiving percutaneous left atrial appendage occlusion (LAAO) with cardiac computed tomography angiography (CTA)-guided preprocedural planning and intracardiac echocardiography (ICE)-guided device deployment.Percutaneous LAAO with the Watchman device (Boston Scientific) is approved by the United States Food and Drug Administration for stroke prevention in patients with non-valvular atrial fibrillation with a demonstrated contraindication to oral anticoagulation. Cardiac CTA preprocedural planning with utilization of an ICE-guided deployment may be associated with favorable outcomes.A prospective analysis of 71 non-consecutive patients who underwent LAAO over an 18-month period with cardiac CTA-guided preprocedural planning and ICE was conducted. Procedures were performed in a single large, academic hospital in the United States. Procedural success, correlation of CTA preprocedural device sizing with final device size utilization, adverse events, length of procedure, and length of stay were evaluated.Preprocedural cardiac CTA-guided device sizing was consistent with the final deployed device in 69 patients (97.2%) evaluated in this case series. Procedure success rate was 100%. All implants were performed using Watchman devices, 45 (63.4%) with the original 2.5 platform and 26 (36.6%) with the Watchman FLX platform. All patients were treated with conscious sedation and the mean length of stay was 1.45 ± 0.72 days. Only 2 adverse events occurred and both resolved.Cardiac CTA-guided preprocedural planning resulted in accurate device sizing in this patient sample and may be used in conjunction with ICE and conscious sedation for a same-day discharge strategy in select patients.
No takes yet. Share an insight, caveat, or question.
Filby et al. (2021) conducted an observational in Non-valvular atrial fibrillation (n=71). Cardiac CTA-guided preprocedural planning and ICE-guided device deployment for LAAO was evaluated on Consistency of preprocedural cardiac CTA-guided device sizing with final deployed device. Cardiac CTA-guided preprocedural planning for left atrial appendage occlusion resulted in accurate device sizing in 97.2% of patients and a 100% procedural success rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: